Gritstone bio (GRTS) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month price targets for Gritstone bio's shares. Their GRTS share price forecasts range from $2.00 to $8.00. On average, they predict the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 197.9% from the stock's current price.
View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts.

Gritstone bio's stock was trading at $3.45 on January 1st, 2023. Since then, GRTS shares have decreased by 44.1% and is now trading at $1.93.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our GRTS earnings forecast.

Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings data on Thursday, March, 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. The firm earned $4.26 million during the quarter, compared to the consensus estimate of $3.08 million. Gritstone bio had a negative net margin of 820.91% and a negative trailing twelve-month return on equity of 81.55%.

ETFs with the largest weight of Gritstone bio (NASDAQ:GRTS) stock in their portfolio include Direxion mRNA ETF (MSGR) and ETFMG Treatments Testing and Advancements ETF (GERM).ALPS Medical Breakthroughs ETF (SBIO).

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

(GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

Gritstone bio trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone bio's stock is owned by many different institutional and retail investors. Top institutional investors include Balyasny Asset Management L.P. (2.67%), BlackRock Inc. (2.17%), Assenagon Asset Management S.A. (1.75%), Bank of America Corp DE (1.19%), FMR LLC (0.90%) and Geode Capital Management LLC (0.84%). Insiders that own company stock include Erin Jones, Raphael Rousseau and Vassiliki Economides.
View institutional ownership trends.

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRTS stock can currently be purchased for approximately $1.93.

Gritstone bio (NASDAQ:GRTS) has a market capitalization of $171.60 million and generates $19.94 million in revenue each year. The company earns $-119,690,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

The company employs 193 workers across the globe.

Gritstone bio's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The official website for the company is www.gritstoneoncology.com. The company can be reached via phone at (510) 871-6100 or via email at ir@gritstone.com.